CEBEDEX

GW Pharma Limited

Application Filed: 2013-06-13

Trademark Application Details

Status

604

Dead/Abandoned

ABANDONED - AFTER INTER-PARTES DECISION

Research	OneLook Acronym Finder
Serial Number	85959221
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Domestic Representative	Michelle L. Visser
Attorney Name	Michelle L. Visser
Attorney Docket Number	66569-0029
Law Office Assigned	L20
Employee Name	REEVES, APRIL ELIZABET

Timeline

2013-06-13	Application Filed
2014-05-13	Published for Opposition
2015-09-21	Abandon
2015-09-21	Location: TTAB
2015-09-21	Status: Dead/Abandoned
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	GW Pharma Limited
Address	Porton Down Science Park Salisbury GB SP4OJR
Legal Entity Type	Corporation
Legal Entity State	GB

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

MICHELLE L VISSER
RADER FISHMAN & GRAUER PLLC
39533 WOODWARD AVE STE 140
BLOOMFIELD HILLS, MI 48304-5098

Good, Services, and Codes

International Codes:	5
U.S. Codes:	006,018,044,046,051,052

Type Code	Type
GS0051	Pharmaceutical and veterinary preparations and substances for the treatment of epilepsy, convulsions, seizures, multiple sclerosis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, crohns disease, alzheimers, bone disorders, drug, alcohol and nicotine abuse; pharmaceutical preparations and substances for the treatment of pediatric epilepsy; pharmaceutical and veterinary preparations and substances for the treatment of Dravet syndrome, hypoxic-ischaemic encephalopathy, Lennox-Gastaut syndrome (LGS), intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), dup 15, and Doose syndrome; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for the treatment of epilepsy, convulsions, seizures, multiple sclerosis, bladder disfunction, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, alzheimers, bone disorders, hypoxic-ischaemic encephalopathy, drug, alcohol and nicotine abuse; pure extracts of medicinal plants and herbs used for the treatment of epilepsy, convulsions, seizures, multiple sclerosis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, alzheimers, hypoxic-ischaemic encephalopathy, bone disorders, drug, alcohol and nicotine abuse; herb teas for medicinal purposes

Type Code

Type

GS0051

Pharmaceutical and veterinary preparations and substances for the treatment of epilepsy, convulsions, seizures, multiple sclerosis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, crohns disease, alzheimers, bone disorders, drug, alcohol and nicotine abuse; pharmaceutical preparations and substances for the treatment of pediatric epilepsy; pharmaceutical and veterinary preparations and substances for the treatment of Dravet syndrome, hypoxic-ischaemic encephalopathy, Lennox-Gastaut syndrome (LGS), intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), dup 15, and Doose syndrome; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for the treatment of epilepsy, convulsions, seizures, multiple sclerosis, bladder disfunction, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, alzheimers, bone disorders, hypoxic-ischaemic encephalopathy, drug, alcohol and nicotine abuse; pure extracts of medicinal plants and herbs used for the treatment of epilepsy, convulsions, seizures, multiple sclerosis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, alzheimers, hypoxic-ischaemic encephalopathy, bone disorders, drug, alcohol and nicotine abuse; herb teas for medicinal purposes

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED IN TRAM	2013-06-17	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2013-06-21	2 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER	2013-09-15	3 DOCK D:Assigned to Examiner
NON-FINAL ACTION WRITTEN	2013-09-19	4 CNRT R:Renewal
NON-FINAL ACTION E-MAILED	2013-09-19	5 GNRT F:First Action
NOTIFICATION OF NON-FINAL ACTION E-MAILED	2013-09-19	6 GNRN O:Outgoing Correspondence
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2014-03-18	7 TROA I:Incoming Correspondence
ASSIGNED TO LIE	2014-03-31	8 ALIE A:Allowance for Publication
CORRESPONDENCE RECEIVED IN LAW OFFICE	2014-04-07	9 CRFA I:Incoming Correspondence
TEAS/EMAIL CORRESPONDENCE ENTERED	2014-04-07	10 TEME I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER	2014-04-08	11 CNSA P:
LAW OFFICE PUBLICATION REVIEW COMPLETED	2014-04-10	12 PREV O:Outgoing Correspondence
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	2014-04-23	13 NONP E:E-Mail
PUBLISHED FOR OPPOSITION	2014-05-13	14 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	2014-05-13	15 NPUB E:E-Mail
EXTENSION OF TIME TO OPPOSE RECEIVED	2014-06-11	16 ETOF T:TTAB Proceeding
TEAS POST PUBLICATION AMENDMENT RECEIVED	2014-11-06	17 EPPA I:Incoming Correspondence
OPPOSITION INSTITUTED NO. 999999	2014-11-10	18 OP.I T:TTAB Proceeding
ASSIGNED TO PETITION STAFF	2014-11-12	19 APET A:Allowance for Publication
CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED	2014-11-13	20 CHPB I:Incoming Correspondence
OPPOSITION SUSTAINED NO. 999999	2015-09-21	21 OP.S T:TTAB Proceeding
OPPOSITION TERMINATED NO. 999999	2015-09-21	22 OP.T T:TTAB Proceeding
ABANDONMENT - AFTER INTER PARTES DECISION	2015-09-21	23 ABN4 O:Outgoing Correspondence
ABANDONMENT NOTICE MAILED - INTER PARTES DECISION	2015-09-21	24 MAB4 O:Outgoing Correspondence

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.